| Přispěvatelé: |
Ilter, Metehan Istanbul Medipol Univ, Sch Engn & Nat Sci, Dept Biomed Engn, TR-34810 Istanbul, Turkey, Mansoor, Samman Istanbul Medipol Univ, Grad Sch Engn & Nat Sci, Dept Biomed Engn & Bioinformat, TR-34810 Istanbul, Turkey, Sensoy, Ozge Istanbul Medipol Univ, Sch Engn & Nat Sci, Dept Comp Engn, TR-34810 Istanbul, Turkey, Mansoor, Samman -- 0000-0002-3367-7566, ILTER, Metehan -- 0000-0003-3579-4552 |
| Popis: |
WOS: 000472631000025 PubMed ID: 31146474 G protein-coupled receptors (GPCRs) are involved in a wide variety of physiological processes. Therefore, approximately 40% of currently prescribed drugs have targeted this receptor family. Discovery of beta-arrestin mediated signaling and also separability of G protein and beta-arrestin signaling pathways have switched the research focus in the GPCR field towards development of biased ligands, which provide engagement of the receptor with a certain effector, thus enriching a specific signaling pathway. In this review, we summarize possible factors that impact signaling profiles of GPCRs such as oligomerization, drug treatment, disease conditions, genetic background, etc. along with relevant molecules that can be used to modulate signaling properties of GPCRs such as allosteric or bitopic ligands, ions, aptamers and pepducins. Moreover, we also discuss the importance of inclusion of pharmacogenomics and molecular dynamics simulations to achieve a holistic understanding of the relation between genetic background and structure and function of GPCRs and GPCR-related proteins. Consequently, specific downstream signaling pathways can be enriched while those that bring unwanted side effects can be prevented on a patient-specific basis. This will improve studies that centered on development of safer and personalized therapeutics, thus alleviating the burden on economy and public health. |
